Schema showing development of the GEM model


In Vivo Capabilities

  • GEM engineering
  • Characterization and validation of GEM models
  • GEM model re-tooling/refinement
  • Adaptation of GEM models to syngeneic allograft models
  • Surgical techniques for generation of murine orthotopic transplant model cohorts
  • Pharmacokinetics and biodistribution of therapeutics in animal models
  •  Pharmacodynamics: evaluation of drug effect on intended target in tumor tissue
  • Evaluation of therapeutic candidates in efficacy studies
  • Cancer prevention studies in GEM models
  • Imaging modalities (MRI, PET/CT, ultrasound, and bioluminescence) 
  • Accurate real-time tumor volume measurements based on live imaging
  • Biomarkers/molecular signatures of treatment response:                                          
  • Immunohistochemical stains
  • Transcriptome
  • Metabolome

In Vitro Capabilities

  • ES cell derivation
  • Primary tumor cell culture establishment
  • iPSC technologies
  • Cell viability assays
  • CRISPR and recombineering allele construction
  • Histopathological assessment
  • Quantitative molecular pathology
  • Evaluation of drug target inhibition